MXLIPO
MCID: MYX005
MIFTS: 57

Myxoid Liposarcoma (MXLIPO) malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Myxoid Liposarcoma

Aliases & Descriptions for Myxoid Liposarcoma:

Name: Myxoid Liposarcoma 54 12 50 66 29 13 14
Myxoid/round Cell Liposarcoma 50 56 69
Liposarcoma, Myxoid 42 69
Liposarcoma 56 69
Mrcls 50 56
Liposarcoma Myxoid 52
Myxoliposarcoma 50
Mxlipo 66

Characteristics:

Orphanet epidemiological data:

56
liposarcoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;
myxoid/round cell liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

HPO:

32
myxoid liposarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 613488
Disease Ontology 12 DOID:5363
MeSH 42 D018208
SNOMED-CT 64 27849002 404069006
MESH via Orphanet 43 D008080 D018208
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 70 C0023827 C0206634
MedGen 40 C0206634
UMLS 69 C0206634

Summaries for Myxoid Liposarcoma

NIH Rare Diseases : 50 myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body’s fat tissue. other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. round cell and myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (mrcls). in adults, liposarcomas are the most common type of soft tissue sarcoma. the cause of liposarcomas is not well-established but trauma has been implicated in some cases. myxoid liposarcomas generally arise in the lower extremities. symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures. when possible, surgical removal is the preferred treatment. in some cases, additional therapy may be indicated. the prognosis is generally favorable for those with a low grade myxoid liposarcoma with a small percentage of round cells. a significant round cell component is associated with a poorer prognosis.  although these tumors rarely spread, they can recur if not completely removed.  last updated: 6/24/2016

MalaCards based summary : Myxoid Liposarcoma, also known as myxoid/round cell liposarcoma, is related to liposarcoma of the ovary and myxoid liposarcoma of the ovary, and has symptoms including abdominal pain, subcutaneous nodule and gastrointestinal dysmotility. An important gene associated with Myxoid Liposarcoma is DDIT3 (DNA Damage Inducible Transcript 3), and among its related pathways/superpathways are Cellular Senescence and Pathways in cancer. The drugs Trabectedin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and kidney, and related phenotypes are cellular and cardiovascular system

OMIM : 54 Myxoid liposarcoma is a soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging... (613488) more...

UniProtKB/Swiss-Prot : 66 Myxoid liposarcoma: A soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion.

Wikipedia : 71 A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance... more...

Related Diseases for Myxoid Liposarcoma

Diseases related to Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 liposarcoma of the ovary 29.9 CDK4 DDIT3 FUS HMGA2 MDM2
2 myxoid liposarcoma of the ovary 12.2
3 cellular myxoid liposarcoma 12.0
4 mixed liposarcoma 11.3
5 liposarcoma 11.0
6 transverse colon cancer 10.2 EWSR1 FUS HMGA2
7 colorectal cancer 1 10.2 DDIT3 EWSR1 FUS
8 bacterial vaginosis 10.2 EWSR1 MDM2
9 primary eye hypotony 10.2 CDK4 MDM2
10 osteomyelitis 10.2 CDK4 MDM2
11 hormone producing pituitary cancer 10.2 CDK4 DDIT3 MDM2
12 acute mountain sickness 10.2 MDM2 TP53
13 amelogenesis imperfecta-gingival hyperplasia syndrome 10.2 CDK4 MDM2
14 pleural lipoma 10.2 CDK4 HMGA2 MDM2
15 sarcoma 10.2
16 childhood immature teratoma of ovary 10.2 CDK4 HMGA2 MDM2
17 aortic aneurysm 10.2 CDK4 MDM2
18 functionless pituitary adenoma 10.2 FUS MDM2 TP53
19 rhabdomyosarcoma 2, alveolar 10.1 CDK4 EWSR1 MDM2
20 blood protein disease 10.1 CDK4 MDM2
21 congenital muscular dystrophy with hyperlaxity 10.1 ERG EWSR1 FUS
22 ectodermal dysplasia 3, witkop type 10.1 CDK4 HMGA2 MDM2
23 bilateral multicystic dysplastic kidney 10.1 ATF1 EWSR1
24 multiple spinal canal and spinal cord meningioma 10.1 ATF1 HMGA2
25 rommen mueller sybert syndrome 10.1 CDK4 MDM2 TP53
26 mediastinum sarcoma 10.1 EWSR1 MDM2 TP53
27 brain stem angioblastoma 10.1 CDK4 MDM2 TP53
28 mediastinum angiosarcoma 10.1 HMGA2 MDM2 TP53
29 intracranial liposarcoma 10.1 CDK4 DDIT3 FUS MDM2
30 prostate rhabdomyosarcoma 10.1 CDK4 EWSR1 TP53
31 enchondromatosis dwarfism deafness 10.1 CDK4 MDM2 TP53
32 pinta disease 10.1 CDK4 DDIT3 FUS MDM2
33 interstitial lung disease 10.1 CDK4 MDM2 TP53
34 extraocular retinoblastoma 10.1 CDK4 MDM2 TP53
35 integumentary system benign neoplasm 10.1 CDK4 MDM2 TP53
36 scarlet fever 10.1 MDM2 TP53
37 post-surgical hypoinsulinemia 10.1 CDK4 MDM2 TP53
38 coronary restenosis 10.1 ATF1 EWSR1 FUS
39 adenosarcoma 10.1 CDK4 MDM2 TP53
40 juvenile xanthogranuloma 10.1 ATF1 EWSR1 FUS
41 ectodermal dysplasia 10.1 CDK4 MDM2 TP53
42 lipoma 10.1
43 lipoblastoma 10.1
44 leukemia 10.1
45 animal phobia 10.0 EWSR1 HMGA2
46 house allergic alveolitis 10.0 CDK4 HMGA2 MDM2 TP53
47 in situ pulmonary adenocarcinoma 10.0 CXCL8 MDM2 TP53
48 thoracic outlet syndrome 10.0 CDK4 EWSR1 MDM2 TP53
49 leiomyoma 10.0
50 mediastinitis 10.0

Graphical network of the top 20 diseases related to Myxoid Liposarcoma:



Diseases related to Myxoid Liposarcoma

Symptoms & Phenotypes for Myxoid Liposarcoma

Clinical features from OMIM:

613488

Human phenotypes related to Myxoid Liposarcoma:

56 32 (show all 11)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 56 32 Occasional (29-5%),Occasional (29-5%) HP:0002027
2 subcutaneous nodule 56 32 Very frequent (99-80%),Very frequent (99-80%) HP:0001482
3 gastrointestinal dysmotility 56 32 Occasional (29-5%) HP:0002579
4 fatigue 56 Occasional (29-5%)
5 nausea and vomiting 56 Occasional (29-5%)
6 weight loss 56 Occasional (29-5%)
7 paresthesia 56 Occasional (29-5%)
8 abnormality of the kidney 56 Occasional (29-5%)
9 sarcoma 56 Very frequent (99-80%)
10 varicose veins 56 Occasional (29-5%)
11 myxoid liposarcoma 32 HP:0012268

MGI Mouse Phenotypes related to Myxoid Liposarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 CDK4 CEBPB CXCL12 DDIT3 ERG HCCS
2 cardiovascular system MP:0005385 10.03 HCCS LRP1 MDM2 TP53 CDK4 CXCL12
3 hematopoietic system MP:0005397 10.02 CDK4 CEBPB CXCL12 DDIT3 ERG LRP1
4 immune system MP:0005387 9.97 CDK4 CEBPB CXCL12 DDIT3 ERG LRP1
5 liver/biliary system MP:0005370 9.8 LRP1 MDM2 TP53 CDK4 CEBPB CXCL12
6 muscle MP:0005369 9.7 CDK4 CEBPB CXCL12 HCCS LRP1 MDM2
7 neoplasm MP:0002006 9.43 CDK4 CEBPB DDIT3 ERG MDM2 TP53
8 normal MP:0002873 9.23 CDK4 CEBPB CXCL12 ERG HCCS LRP1

Drugs & Therapeutics for Myxoid Liposarcoma

Drugs for Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
3
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
4
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
8
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
9
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
10
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
11
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
12 Alkylating Agents Phase 3,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
16 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2
19 Antimetabolites Phase 3,Phase 2
20 Antimetabolites, Antineoplastic Phase 3,Phase 2
21 Antimitotic Agents Phase 3
22 Antineoplastic Agents, Phytogenic Phase 3
23 Antiviral Agents Phase 3,Phase 2
24 Etoposide phosphate Phase 3
25 Isophosphamide mustard Phase 3,Phase 2
26
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
27
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
28
Everolimus Approved Phase 2 159351-69-6 6442177
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
31
Maleic acid Experimental Phase 2 110-16-7 444266
32 Antiemetics Phase 2
33 Anti-Inflammatory Agents Phase 2
34 Antineoplastic Agents, Hormonal Phase 2
35 Autonomic Agents Phase 2
36 BB 1101 Phase 2
37 Dexamethasone 21-phosphate Phase 2
38 Dexamethasone acetate Phase 2 1177-87-3
39 Gastrointestinal Agents Phase 2
40 glucocorticoids Phase 2
41 HIV Protease Inhibitors Phase 2
42 Hormone Antagonists Phase 2
43 Hormones Phase 2
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
45 Peripheral Nervous System Agents Phase 2
46
protease inhibitors Phase 2
47 Antibodies Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2,Phase 1
49 Immunoglobulins Phase 2,Phase 1
50 insulin Phase 2

Interventional clinical trials:

(show all 21)
id Name Status NCT ID Phase
1 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
2 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
3 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2
4 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2
5 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2
6 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2
7 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2
8 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
9 Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas Recruiting NCT02106312 Phase 2
10 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2
11 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Recruiting NCT02249949 Phase 2
12 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Recruiting NCT02275286 Phase 1, Phase 2
13 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 1, Phase 2
14 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Recruiting NCT02609984 Phase 2
15 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
16 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Active, not recruiting NCT01692496 Phase 2
17 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2
18 Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Completed NCT01477021 Phase 1
19 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1
20 NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Withdrawn NCT02059850 Phase 1
21 Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Recruiting NCT01957709

Search NIH Clinical Center for Myxoid Liposarcoma

Cochrane evidence based reviews: liposarcoma, myxoid

Genetic Tests for Myxoid Liposarcoma

Genetic tests related to Myxoid Liposarcoma:

id Genetic test Affiliating Genes
1 Myxoid Liposarcoma 29

Anatomical Context for Myxoid Liposarcoma

MalaCards organs/tissues related to Myxoid Liposarcoma:

39
Bone, Breast, Kidney, Myeloid, Liver, Thyroid, Ovary

Publications for Myxoid Liposarcoma

Articles related to Myxoid Liposarcoma:

(show top 50) (show all 289)
id Title Authors Year
1
MRI characteristics associated with high-grade myxoid liposarcoma. ( 28256200 )
2017
2
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
3
Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. ( 28160093 )
2017
4
Resectable primary pleural myxoid liposarcoma with a pedicle: report of a rare case and literature review. ( 28449500 )
2017
5
Primary lesser sac myxoid liposarcoma: A case report. ( 27176503 )
2016
6
Myxoid liposarcoma with pleomorphic cells: Report of two cases with molecular confirmation of FUS gene rearrangements. ( 27515548 )
2016
7
Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma. ( 27822137 )
2016
8
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. ( 26897615 )
2016
9
miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. ( 27157622 )
2016
10
High-Grade Myxoid Liposarcoma (Round Cell Variant) in a Dog. ( 27665042 )
2016
11
Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease. ( 26831007 )
2016
12
Myxoid liposarcoma of the hand - A rare entity. ( 28018076 )
2016
13
Lipoblastoma presenting as a rapidly growing paravertebral mass and masquerading as myxoid liposarcoma on fine needle aspiration cytology. ( 26919610 )
2016
14
Soft tissue uptake of 99mTc-MDP in a case of myxoid liposarcoma with breast metastasis. ( 28292146 )
2016
15
Primary dumbbell-shaped epidural myxoid liposarcoma of the thoracic spine: A case report and review of the literature. ( 26893754 )
2016
16
Cystic Pulmonary Myxoid Liposarcoma Mimicking Endobronchial Blood Clot. ( 27058719 )
2016
17
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. ( 27401457 )
2016
18
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. ( 27270875 )
2016
19
Myxoid liposarcoma of the foot: a study of 8 cases. ( 27806844 )
2016
20
Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma. ( 27511215 )
2016
21
Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. ( 27026512 )
2016
22
Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. ( 25562433 )
2015
23
FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. ( 26036639 )
2015
24
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. ( 27499900 )
2015
25
Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. ( 24917554 )
2015
26
Extensive lipoma-like changes of myxoid liposarcoma: morphologic, immunohistochemical, and molecular cytogenetic analyses. ( 25650275 )
2015
27
Retroperitoneal perirenal myxoid liposarcoma. ( 25750026 )
2015
28
Limb-sparing surgery as an alternative for limb amputation in an invasive myxoid liposarcoma - case report. ( 25866581 )
2015
29
Successful salvage treatment of myxoid liposarcoma with multiple peritoneal seeding using helical tomotherapy-based intraperitoneal radiotherapy: a case report. ( 25930065 )
2015
30
Mesenteric metastases of purely myxoid liposarcoma: An unusual behavior of primary tumor depicted on fludeoxyglucose positron emission tomography/computerized tomography. ( 25589817 )
2015
31
Comprehensive genetic analysis of a pediatric pleomorphic myxoid liposarcoma reveals near-haploidization and loss of the RB1 gene. ( 26647907 )
2015
32
The co-existence of a myxoid liposarcoma and leiomyoma in the same ovarian mass of a dog. ( 26522811 )
2015
33
Vulvar Myxoid Liposarcoma and Well Differentiated Liposarcoma With Molecular Cytogenetic Confirmation: Case Reports With Review of Malignant Lipomatous Tumors of the Vulva. ( 25851712 )
2015
34
Metastasis of myxoid liposarcoma to fat-bearing areas: A case report of unusual metastatic sites and a hypothesis. ( 26622886 )
2015
35
Mediastinal Myxoid Liposarcoma with Intrapericardial Involvement and Large Pericardial Effusion. ( 26509343 )
2015
36
Primary myxoid liposarcoma of the ovary in a postpartum female: a case report and review of literature. ( 25760901 )
2015
37
Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. ( 26225840 )
2015
38
Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. ( 25747531 )
2015
39
Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up. ( 25583234 )
2015
40
Giant myxoid liposarcoma of descending mesocolon origin. ( 25653732 )
2014
41
Metachronous multifocal myxoid liposarcoma involving the gastrointestinal tract. Management and literature review. ( 24678225 )
2014
42
Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. ( 24788530 )
2014
43
Array-based comparative genomic hybridisation analysis of a pleomorphic myxoid liposarcoma. ( 24970901 )
2014
44
Identification of a gene expression driven progression pathway in myxoid liposarcoma. ( 25115389 )
2014
45
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. ( 24726063 )
2014
46
Primary Subcutaneous Myxoid Liposarcoma - A Clinicopathologic Review of 3 Cases with Molecular Confirmation and Discussion of the Differential Diagnosis. ( 25376660 )
2014
47
Multicentric myxoid liposarcoma; a case report and literature review. ( 25207321 )
2014
48
A case of myxoid liposarcoma of the retroperitoneum: a challenging tumour for diagnosis and treatment. ( 25024863 )
2014
49
Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedin. ( 24803896 )
2014
50
Solitary breast metastasis from myxoid liposarcoma. ( 24994066 )
2014

Variations for Myxoid Liposarcoma

Cosmic variations for Myxoid Liposarcoma:

9 (show all 34)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 27
2 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 27
3 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 27
4 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 27
5 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 27
6 COSM10654 TP53 soft tissue,fat,liposarcoma,well differentiated c.637C>T p.R213* 19
7 COSM11059 TP53 soft tissue,fat,liposarcoma,well differentiated c.713G>A p.C238Y 19
8 COSM6901 TP53 soft tissue,fat,liposarcoma,well differentiated c.559+1G>A p.? 19
9 COSM10941 TP53 soft tissue,fat,liposarcoma,well differentiated c.730G>A p.G244S 19
10 COSM44512 TP53 soft tissue,fat,liposarcoma,well differentiated c.740A>G p.N247S 19
11 COSM11245 TP53 soft tissue,fat,liposarcoma,well differentiated c.430C>T p.Q144* 19
12 COSM44723 TP53 soft tissue,fat,liposarcoma,well differentiated c.674T>C p.V225A 19
13 COSM44094 TP53 soft tissue,fat,liposarcoma,well differentiated c.716A>G p.N239S 19
14 COSM43663 TP53 soft tissue,fat,liposarcoma,well differentiated c.826G>C p.A276P 19
15 COSM10646 TP53 soft tissue,fat,liposarcoma,well differentiated c.725G>A p.C242Y 19
16 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 19
17 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 19
18 COSM775 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.3140A>G p.H1047R 19
19 COSM12458 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1634A>C p.E545A 19
20 COSM25083 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1627A>G p.I543V 19
21 COSM21467 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1612G>A p.D538N 19
22 COSM760 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1624G>A p.E542K 19
23 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 19
24 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 19
25 COSM532 KRAS soft tissue,fat,liposarcoma,well differentiated c.38G>A p.G13D 19
26 COSM1290 KIT soft tissue,fat,liposarcoma,well differentiated c.1727T>C p.L576P 19
27 COSM487 HRAS soft tissue,fat,liposarcoma,well differentiated c.37G>A p.G13S 19
28 COSM480 HRAS soft tissue,fat,liposarcoma,well differentiated c.34G>A p.G12S 19
29 COSM720 FGFR3 soft tissue,fat,liposarcoma,well differentiated c.1949A>T p.K650M 19
30 COSM601 FGFR1 soft tissue,fat,liposarcoma,well differentiated c.374C>T p.S125L 19
31 COSM5676 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.122C>T p.T41I 19
32 COSM5708 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.119C>T p.T40I 19
33 COSM5743 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.117C>T p.A39A 19
34 COSM476 BRAF soft tissue,fat,liposarcoma,well differentiated c.1799T>A p.V600E 19

Expression for Myxoid Liposarcoma

Search GEO for disease gene expression data for Myxoid Liposarcoma.

Pathways for Myxoid Liposarcoma

Pathways related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 CDK4 CEBPB CXCL8 HMGA2 MDM2 TP53
2 12.47 CDK4 CXCL12 CXCL8 MDM2 TP53
3 12.18 ERG EWSR1 FUS HMGA2
4
Show member pathways
12.05 ATF1 CEBPB CXCL8 TP53
5 11.89 ATF1 CDK4 MDM2 TP53
6 11.88 CDK4 MDM2 TP53
7 11.82 CDK4 CXCL8 TP53
8 11.78 CDK4 MDM2 TP53
9 11.67 CDK4 MDM2 TP53
10 11.65 CEBPB CXCL8 MDM2 TP53
11 11.63 CXCL8 MDM2 TP53
12 11.62 ATF1 CEBPB CXCL8 DDIT3 ERG EWSR1
13 11.42 CDK4 CXCL8 MDM2 TP53
14 11.41 CDK4 CXCL8 DDIT3
15 11.25 CDK4 MDM2 TP53
16 11.12 ATF1 CDK4 MDM2 TP53
17 11.05 CDK4 MDM2 TP53
18 10.93 MDM2 TP53
19
Show member pathways
10.93 MDM2 TP53
20 10.8 ATF1 CEBPB DDIT3 TP53

GO Terms for Myxoid Liposarcoma

Cellular components related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.73 ATF1 CDK4 CEBPB DDIT3 ERG EWSR1
2 CHOP-C/EBP complex GO:0036488 8.62 CEBPB DDIT3

Biological processes related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.93 ATF1 CEBPB DDIT3 ERG HMGA2 TP53
2 cell proliferation GO:0008283 9.85 ERG HMGA2 LRP1 TP53
3 transcription from RNA polymerase II promoter GO:0006366 9.83 ATF1 CEBPB ERG HMGA2 TP53
4 regulation of transcription, DNA-templated GO:0006355 9.81 ATF1 CEBPB DDIT3 ERG EWSR1 FUS
5 negative regulation of transcription, DNA-templated GO:0045892 9.72 CEBPB DDIT3 HMGA2 MDM2 TP53
6 cellular response to lipopolysaccharide GO:0071222 9.7 CDK4 CEBPB CXCL8
7 negative regulation of cell cycle arrest GO:0071157 9.54 CDK4 MDM2
8 positive regulation of protein export from nucleus GO:0046827 9.49 MDM2 TP53
9 induction of positive chemotaxis GO:0050930 9.48 CXCL12 CXCL8
10 response to endoplasmic reticulum stress GO:0034976 9.43 CEBPB CXCL8 DDIT3
11 PERK-mediated unfolded protein response GO:0036499 9.4 CXCL8 DDIT3
12 ER overload response GO:0006983 9.37 DDIT3 TP53
13 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
14 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 8.8 CEBPB DDIT3 TP53
15 transcription, DNA-templated GO:0006351 10.11 ATF1 CEBPB DDIT3 ERG EWSR1 HMGA2

Molecular functions related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.26 CEBPB DDIT3 HMGA2 TP53
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 8.92 CEBPB DDIT3 ERG HMGA2

Sources for Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....